Black Diamond Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Main St Ste 14, Cambridge, Massachuset...Phone Number
(617) 252-0848Revenue
-Stock Symbol
BDTXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
1
1
About Black Diamond Therapeutics
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company's proprietary technology platform and drug discovery engine, the Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy that targets a specific family of mutations, termed a MasterKey therapy.Explore more
Black Diamond Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Black Diamond Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Black Diamond Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Black Diamond Therapeutics is spiking on competitors!
Black Diamond Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Black Diamond Therapeutics has new funding data
Click to see if Black Diamond Therapeutics had a recent Job posting/layoffs
Check if Black Diamond Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Black Diamond Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Black Diamond Therapeutics launches new products
Recommended Actions
Find VP level buyers at Black Diamond Therapeutics
Find 3 more new buyers
Compare Similar Companies to Black Diamond Therapeutics
Compare insights from companies similar to Black Diamond Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Black Diamond Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Black Diamond Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Black Diamond Therapeutics.
Black Diamond Therapeutics financials insights
Gather financial insights about Black Diamond Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$20M
2019
Series B
$85M
Series C
$85M
2020
Stock Offering
$231M
Black Diamond Therapeutics Tech Stack
A closer look at the technologies used by Black Diamond Therapeutics
Most Recent Scoops
Person-Based
Medical Research
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Black Diamond Therapeutics has initiated a randomized Phase II trial of BDTX-1535 in combination with standard-of-care temozolomide versus temozolomide alone in newly diagnosed glioblastoma patients following surgery and chemoradiation, with the first cohort already enrolled and data expected in H1 2028.
Medical Research, Pharmaceuticals, Clinical Operations
Project
plans to request an FDA meeting in Q3, with feedback expected in early Q4, to determine the fastest regulatory approval path for silevertinib, including potential strategies such as a randomized trial for patients with CNS disease at diagnosis and a single-arm path for patients with PACC mutations.
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Events
Top Business Services Companies
Frequently Asked Questions Regarding Black Diamond Therapeutics
Sign Up For FreeTo access detailed company insights
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company's propr... Read More
